India's CRDMO sector is set to grow to $22-25 billion by 2035, driven by global pharma realignments and innovation. A BCG-IPSO report highlights India's strengths in small molecules, biologics, and cost efficiency. Eleven CRDMOs have formed IPSO to boost India's role in the global pharmaceutical value chain.